[PDF][PDF] Design and optimization of rivaroxaban-cyclodextrin-polymer triple complex formulation with improved solubility
Purpose This study aimed to ensure the convenience of administration and reproducibility of
efficacy, regardless of the meal, by improving the solubility of rivaroxaban (RIV). Methods …
efficacy, regardless of the meal, by improving the solubility of rivaroxaban (RIV). Methods …
Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation
S Park, NK Je - Journal of Cardiovascular Pharmacology …, 2021 - journals.sagepub.com
Background: Major atrial fibrillation (AF) guidelines recommend non-vitamin K antagonist
oral anticoagulants (NOACs) over warfarin, except in rare clinical circumstances based on 4 …
oral anticoagulants (NOACs) over warfarin, except in rare clinical circumstances based on 4 …
[HTML][HTML] Real World Outcomes of Direct Oral Anticoagulant in End Stage Kidney Disease on Dialysis
MS Lee, YW Choi, SM Kim, GN Park… - Journal of Korean Dialysis …, 2024 - e-jkda.org
Background: Patients with end stage kidney disease (ESKD) are at an increased risk of both
thromboembolic events and bleeding. Direct oral anticoagulant (DOAC) agents has been …
thromboembolic events and bleeding. Direct oral anticoagulant (DOAC) agents has been …